Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program.

ABSTRACT: BACKGROUND:Glembatumumab vedotin is an antibody-auristatin conjugate that targets cells expressing the transmembrane glycoprotein NMB (GPNMB, also known as osteoactivin). It has entered clinical evaluation for adult cancers that express GPNMB, including melanoma and breast cancer. PROCEDURES:Glembatumumab vedotin was administered intravenously at a dose of 2.5?mg/kg using a weekly?×?3 schedule, and its antitumor activity was evaluated against selected Pediatric Preclinical Testing Program (PPTP) solid tumor xenografts using standard PPTP response metrics. RESULTS:Among PPTP xenografts, GPNMB was primarily expressed on the osteosarcoma xenografts, all of which expressed GPNMB at the RNA level, although at varying levels. Protein expression assessed by immunohistochemistry (IHC) showed variation across the osteosarcoma xenografts with one model showing no tumor cell expression. Glembatumumab vedotin induced statistically significant differences (P?

SUBMITTER: Kolb EA 

PROVIDER: S-EPMC4280502 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature